Qare™ Is Here: Lōkahi Therapeutics™ Launches a Proprietary New Way to Compare Your Care, Beginning with GLP — 1 Medications

For best results when printing this announcement, please click on link below: Qare™ Is Here: Lōkahi Therapeutics™ Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 Medications Now free on the App Store and Google Play, Qare matches users into cohorts by medication and demographic profile, generating a database of user-reported real-world experience data that Lōkahi believes may become a source of long-term value to patients and manufacturers Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc.

(NASDAQ: GCTK), today announced the public launch of Qare™, a comparative health platform designed to help users compare self-reported treatment experiences across medications within the same therapeutic class. Launching initially in the GLP-1 category, Qare™ enables users to compare their self-reported results, side effects, and out-of-pocket costs against people with a similar profile, whether they take the same medication or a different one in the class. Cohort comparisons are presented in aggregate, and Qare’s data infrastructure is hosted by third-party providers that maintain SOC 2 and ISO 27001 certifications.

” By placing each user’s results in the context of a matched cohort, Qare turns individual records into comparative insight. “Healthcare data is a big business that many times misses in delivering actionable value for patients, providers and manufacturers. Lōkahi looks to address that,” said Erik Emerson, Chief Executive Officer of Lōkahi Therapeutics™. ” “People on GLP-1s and many other medications have tools to record their experience, but very little context for what their results mean,” said Anna Lewandowski, Director, ai² Division.

“Qare is designed to provide that context. ” Qare™ was developed through ai² Accelerator™, an extension of Lōkahi’s ai² platform and university partnerships which is focused on leveraging technology to improve healthcare. The initial launch focuses on GLP-1 medications. Lōkahi expects to add other therapeutic categories to Qare™, via organic expansion and industry partnerships.

As the user base grows, Qare is designed to generate an increasingly granular, de-identified real-world dataset, which Lōkahi believes may support future research and industry partnerships. Qare™ is now publicly available. com to learn more. About Lōkahi Therapeutics™ Lōkahi Therapeutics is a capital-efficient biopharmaceutical platform company focused on identifying, evaluating, acquiring, and advancing overlooked therapeutic assets.

Through its ai² platform and ai² Futures Lab execution model, Lōkahi integrates cross-functional expertise and disciplined decision-making to drive strategic development and long-term value creation. For more information, please visit ( ). For more information about the ai² Division program, please visit ( ). Information on the company’s websites does not constitute a part of and is not incorporated by reference into this press release.

About Glucotrack, Inc. Glucotrack, Inc. , is also focused on the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring system. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.

For more information, please visit ( ). Information on the company’s website does not constitute a part of and is not incorporated by reference into this press release. Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements.

Without limiting the generality of the foregoing, words such as "anticipate,” "believe,” "expect,” "plan," “intend,” “may,” “potential,” “designed to,” and "will" are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. S.

Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026, and subsequent Quarterly Reports on Form 10-Q. com)